Crossref
EE474 BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS
Value in Health · 2026-06 · 29 (6) · S152
DOI: 10.1016/j.jval.2026.03.767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Yuanbao Xie und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Xie, Y., Chen, Y., Wu, J., Yuan, X., Duan, X., Liu, F., & HU, M. (2026). EE474 BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS. Value in Health, 29(6), S152. https://doi.org/10.1016/j.jval.2026.03.767
Vancouver
Xie Y, Chen Y, Wu J, Yuan X, Duan X, Liu F, et al. EE474 BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS. Value in Health. 2026;29(6):S152. doi:10.1016/j.jval.2026.03.767
BibTeX
@article{Xie2026,
author = {Xie, Yuanbao and Chen, Yu and Wu, Jingjing and Yuan, Xinyue and Duan, xianghui and Liu, Fei and HU, MING},
title = {EE474 BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S152},
doi = {10.1016/j.jval.2026.03.767}
}
EUVIMED